Many Investors Still Treating Gilead: 4 Launches This Year Could Prove Them Wrong
Gilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Zero Based Budgeting Strategies For Variable Income presents practical tactics to budget around fluctuating earnings and protect finances.
21,687 articlesGilead sits at a crossroads: the HIV backbone remains strong, but a quartet of new launches could reshape the company...
Palantir surges on AI hype while Salesforce shows real earnings growth and cash flow. This piece explains why investo...
A new framework around Michael Saylor's strategy approach reshapes how Bitcoin is bought and sold. This article unpac...
Investors are buzzing about what happening with quantumscape. This article breaks down the core catalysts, risks, and...
Cyclops, a Miami-based payments infrastructure startup, closed a $20 million Series A to accelerate settlement speeds...
AMD is positioning itself as a robust player across consumer, data center, and AI markets. This article breaks down w...
Brookstone Capital's 13F reveals a modest stake in the XRP ETF, but viral posts claim a $71 million position due to a...
Beaten-down brands aren’t a bet on luck—they’re a test of resilience. This piece explores two stocks down right hold ...
Air-taxi darlings Joby, Archer, and EHang have fallen sharply in 2026 as cert timelines and cash burn loom large. Inv...
Two families file a civil case after DNA tests revealed a birth swap at Unity Medical Center in 1988, challenging hos...
Palantir trades at lofty multiples, but its growth engine is real. This piece weighs the high valuation against the b...
XRP rallied on whispers of regulatory clarity, but the price action is tempered by cautious charts. This deep dive ex...